Next Article in Journal
Induced Pluripotent Stem Cell-Based Cancer Immunotherapy: Strategies and Perspectives
Previous Article in Journal
Evaluation of the Effectiveness and Accuracy of Non-Invasive Preimplantation Genetic Testing (niPGT) Compared to Invasive Embryo Biopsy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Yan et al. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer. Biomedicines 2025, 13, 882

1
Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
2
Department of Pathology, Zhengzhou People’s Hospital, Fifth Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450003, China
3
Centre for Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
*
Author to whom correspondence should be addressed.
Biomedicines 2025, 13(8), 2011; https://doi.org/10.3390/biomedicines13082011
Submission received: 4 July 2025 / Accepted: 18 July 2025 / Published: 19 August 2025
(This article belongs to the Section Immunology and Immunotherapy)

Error in Figure

In the original publication [1], there was a mistake in Figure 2A as published. Specifically, three image panels (CD8 and F4/80 staining on Day 10) were inadvertently duplicated during the figure rearrangement process. The corrected Figure 2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Yan, W.; Xuan, Y.; Wang, R.; Huan, Z.; Guo, Y.; Dun, H.; Xu, L.; Han, R.; Sun, X.; Si, L.; et al. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer. Biomedicines 2025, 13, 882. [Google Scholar] [CrossRef]
Figure 2. Immune cell profiles of tumor tissue, spleen, and draining lymph nodes of mice after treatments. (A) Quantification of immune cell populations in tumor tissues over time post-treatment. Immunohistochemistry (IHC) assay was used to assess the presence of CD3+ T-cells, CD4+ T-cells, CD8+ T-cells, and macrophages (F4/80+) on days 7, 10, and 15 post-treatments with PBS, VVΔTK, or VVL-DD. Representative images of IHC staining for CD3+ T-cells, CD4+ T-cells, CD8+ T-cells, and macrophages on day 10. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. (B,C) Spleen and lymph node specimens harvested on post-treatment days 7/10/15; flow cytometric analysis of tissue-derived single-cell suspensions for lymphocyte profiling (n = 3). Data represent mean ± SEM, with two-way ANOVA used for statistical comparisons (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Figure 2. Immune cell profiles of tumor tissue, spleen, and draining lymph nodes of mice after treatments. (A) Quantification of immune cell populations in tumor tissues over time post-treatment. Immunohistochemistry (IHC) assay was used to assess the presence of CD3+ T-cells, CD4+ T-cells, CD8+ T-cells, and macrophages (F4/80+) on days 7, 10, and 15 post-treatments with PBS, VVΔTK, or VVL-DD. Representative images of IHC staining for CD3+ T-cells, CD4+ T-cells, CD8+ T-cells, and macrophages on day 10. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. (B,C) Spleen and lymph node specimens harvested on post-treatment days 7/10/15; flow cytometric analysis of tissue-derived single-cell suspensions for lymphocyte profiling (n = 3). Data represent mean ± SEM, with two-way ANOVA used for statistical comparisons (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Biomedicines 13 02011 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yan, W.; Xuan, Y.; Wang, R.; Huan, Z.; Guo, Y.; Dun, H.; Xu, L.; Han, R.; Sun, X.; Si, L.; et al. Correction: Yan et al. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer. Biomedicines 2025, 13, 882. Biomedicines 2025, 13, 2011. https://doi.org/10.3390/biomedicines13082011

AMA Style

Yan W, Xuan Y, Wang R, Huan Z, Guo Y, Dun H, Xu L, Han R, Sun X, Si L, et al. Correction: Yan et al. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer. Biomedicines 2025, 13, 882. Biomedicines. 2025; 13(8):2011. https://doi.org/10.3390/biomedicines13082011

Chicago/Turabian Style

Yan, Wenyi, Yujing Xuan, Ruimin Wang, Ziyan Huan, Yu Guo, Huilin Dun, Lihua Xu, Ruxia Han, Xianlei Sun, Lingling Si, and et al. 2025. "Correction: Yan et al. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer. Biomedicines 2025, 13, 882" Biomedicines 13, no. 8: 2011. https://doi.org/10.3390/biomedicines13082011

APA Style

Yan, W., Xuan, Y., Wang, R., Huan, Z., Guo, Y., Dun, H., Xu, L., Han, R., Sun, X., Si, L., Lemoine, N. R., Wang, Y., & Wang, P. (2025). Correction: Yan et al. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer. Biomedicines 2025, 13, 882. Biomedicines, 13(8), 2011. https://doi.org/10.3390/biomedicines13082011

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop